In the last decade, tocilizumab (an anti-IL-6 biological) has been reported to successfully suppress SAA levels in polyarteritis nodosa [70] and RA [71] and was proven successful in regulating AA amyloidosis itself, even causing regression of amyloid plaques [72]. Here, SAA2 is linked to rheumatoid arthritis.